SUBSCRIBE
SUBSCRIBE

Neurodegenerative disease

A brain hovers over a hand against a yellow-striped background
Neuroscience
5 Neuro Data Readouts to Watch in the Second Half of 2024
After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and neurodegenerative disease spaces during the next six months.
July 15, 2024
 · 
6 min read
 · 
Heather McKenzie
A scientist studies genes on a computer screen
Parkinson’s disease
Breaking the Cycle of Inflammation in Parkinson’s Disease
Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression.
July 15, 2024
 · 
4 min read
 · 
Jill Drachenberg
Load More
PRESS RELEASES
Press Releases
Dewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment of ALS and Related Neurodegenerative Diseases
January 9, 2026
 · 
3 min read
Press Releases
VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS
January 8, 2026
 · 
3 min read
Press Releases
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
January 8, 2026
 · 
6 min read
Press Releases
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
January 8, 2026
 · 
9 min read
Press Releases
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
January 6, 2026
 · 
4 min read
Press Releases
Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson’s Disease
January 5, 2026
 · 
4 min read
Press Releases
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
December 23, 2025
 · 
5 min read
Press Releases
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA
December 23, 2025
 · 
9 min read
Press Releases
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
December 19, 2025
 · 
7 min read
Press Releases
Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases
December 10, 2025
 · 
4 min read
Press Releases
Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore
December 10, 2025
 · 
3 min read
Press Releases
Lunai Bioworks Identifies Three Parkinson’s Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
December 10, 2025
 · 
4 min read
Press Releases
Profluent Bio Announces Strategic Collaboration with Ensoma to Develop AI-Designed Base Editors for In Vivo Hematopoietic Stem Cell Therapies
December 10, 2025
 · 
2 min read
Press Releases
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
December 10, 2025
 · 
6 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
MJFF Initiates Funding for Emerging Therapeutic Targets in Parkinson’s Disease
December 9, 2025
 · 
4 min read
Press Releases
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
December 9, 2025
 · 
7 min read
Press Releases
Circular Genomics Strengthens Scientific Advisory Board with the Addition of Esteemed Alzheimer’s Experts
December 9, 2025
 · 
3 min read
Press Releases
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
December 5, 2025
 · 
8 min read
Press Releases
Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
December 5, 2025
 · 
5 min read
Load More